Özet:

Aim: Helicobacter pylori, can cause ulcer, gastric atrophy, intestinal metaplasia, and gastric adenocarcinoma. In this study, it was aimed to compare the H. pylori eradication rates obtained with the combined treatments used in H. pylori eradication and the addition of bismuth subcitrate (BS) to these treatments. Material and Methods: 190 patients who were found to have H. pylori in endoscopic biopsy in the gastroenterological surgery clinic of Mersin City Training and Research Hospital between January 2019 and January 2022 and used 14-day 1- classical triple therapy, 2- classical triple therapy + BS, 3- proton pump inhibitors (PPI) + amoxicillin-clavulanic acid + metranidazol, and 4- combination of PPI + amoxicillin-clavulanic acid + metranidazol + BS for 14 days for HP eradication, were retrospectively divided into 4 groups and included in the study. Results: Of 190 patients enrolled in the study, 85 (44.70%) were male and 105 (55.30%) were female; the mean age of the study population was 41.9 years. H. pylori eradication was successful in 33 (75%) of 44 (23.20%) patients who used the classical triple therapy; 33 (75%) of 44 (23.20%) patients who used the classical triple therapy + BS; 35 (81.39%) of 42 (22.60%) patients who used PPI + amoxicillin-clavulanic acid + metranidazol; and 54 (88.52%) of 61 (32.10%) patients who used PPI + amoxicillin-clavulonic acid + metranidazol + BS (p=0.027). H. pylori eradication success was statistically significant in each of the four groups (p<0.05). Conclusion: Adding BS to combination therapies increased the success rates in H. pylori eradication. Successful H. pylori eradication depends on the treatment regimen chosen, patient compliance, and antibiotic resistance.